Please login to the form below

Not currently logged in
Email:
Password:

Ischemix names David DeWahl as CEO

He joins the US biotech from private investment firm Colchester Healthcare Investments

David DeWahl has been appointed president and CEO of US biotech Ischemix.

He joins after stepping down from his role as president of private investment firm Colchester Healthcare Investments.

He has also previously served as VP corporate development at Helix Therapeutics and managing director at Life Science Group – a company he co-founded.

Prior to that, DeWahl was an investment banker with a focus on healthcare the life sciences.

“His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Dr Reinier Beeuwkes, chairman of the board and chief scientific officer at Ischemix.

These candidates include the company's lead compound CMX-2043, which is being developed to protect against heart and kidney damage due to the interruption of blood flow.

The investigational drug has recently demonstrated positive benefits in phase IIa trials, and further development is expected this year.

11th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics